An open multicentre study on the efficacy and safety of rufloxacin in patients with chronic bacterial prostatitis.

Abstract

In an open study, 27 patients with chronic bacterial prostatitis were treated for four weeks with rufloxacin. They received 400 mg on the first day, and then 200 mg once daily. The patients were studied for up to one month after completion of therapy. One patient was lost to follow-up, but was included in the safety analysis. One patient did not meet all the inclusion criteria (WBC less than 10/HPF in the prostatic fluid sample) and was evaluated separately (cure). One month after treatment, clinical success (cure and improvement) was obtained in 23 of 25 patients (92%) and bacteriological eradication was achieved in 19 of 24 patients (79%). The only adverse event possibly related to the study drug was a case of transient mild tiredness and nervousness. Rufloxacin did not accumulate in plasma during therapy. Hence, a single daily dose of rufloxacin 200 mg appears to be a safe treatment for chronic bacterial prostatitis.

• Authors: J B Boerema, W Bischoff, J Focht, K G Naber
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 28 Issue 4 Pg. 587-97 (Oct 1991) ISSN: 0305-7453 [Print] England
• PMID: 1662192 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Quinolones
• rufloxacin

Topics

• Adult
• Anti-Infective Agents (therapeutic use)
• Bacterial Infections (blood, drug therapy, microbiology)
• Chronic Disease
• Fluoroquinolones
• Humans
• Male
• Middle Aged
• Prostatitis (blood, drug therapy, microbiology)
• Quinolones (therapeutic use)